Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $79.8 million.

  • Madrigal Pharmaceuticals' Cash from Operations rose 21920.76% to $79.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$160.6 million, marking a year-over-year increase of 6274.43%. This contributed to the annual value of -$455.6 million for FY2024, which is 4050.89% down from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Cash from Operations stood at $79.8 million, which was up 21920.76% from -$47.1 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Cash from Operations registered a high of $79.8 million during Q3 2025, and its lowest value of -$149.2 million during Q1 2024.
  • For the 5-year period, Madrigal Pharmaceuticals' Cash from Operations averaged around -$65.5 million, with its median value being -$59.1 million (2022).
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 9326.0% in 2021, then soared by 21920.76% in 2025.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Cash from Operations stood at -$48.1 million in 2021, then fell by 21.78% to -$58.5 million in 2022, then tumbled by 36.6% to -$79.9 million in 2023, then tumbled by 30.72% to -$104.5 million in 2024, then skyrocketed by 176.42% to $79.8 million in 2025.
  • Its Cash from Operations stands at $79.8 million for Q3 2025, versus -$47.1 million for Q2 2025 and -$88.9 million for Q1 2025.